Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment-Reference-Cited by-同舟云学术

Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment

Published:2019-05-29 Issue:9 Volume:49 Page:1054-1065
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Kuzuya Teiji¹,Ishigami Masatoshi¹,Ito Takanori¹^ORCID,Ishizu Yoji¹,Honda Takashi¹,Ishikawa Tetsuya¹,Hirooka Yoshiki¹,Fujishiro Mitsuhiro¹

Affiliation:

1. Department of Gastroenterology and HepatologyNagoya University Graduate School of Medicine Nagoya Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13358

Reference27 articles.

1. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

2. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

3. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

4. Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma

5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma;Current Oncology;2024-07-26

2. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib;Molecular and Clinical Oncology;2024-07-10

3. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis;Journal of Cancer Research and Clinical Oncology;2023-09-02

4. Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors;Journal of Medicinal Chemistry;2023-06-19

5. Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma;Cancer Medicine;2023-05-10